For which indications are 177lu Dotatate peptide receptor radionuclide therapy approved by the FDA? - Revive Hormone Clinic

177Lu Dotatate, also known as Lutathera, is a radiopharmaceutical therapy that has been approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Some key points about Lutathera's FDA-approved indications:

In the pivotal trial that led to its approval (NETTER-1), Lutathera demonstrated: The specific indications statement in Lutathera's FDA-approved labeling is:
"LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults."
Some additional context around Lutathera and neuroendocrine tumors: If you have been diagnosed with inoperable, metastasized GEP-NETs and are looking for advanced treatment options, speak to your oncologist about whether 177Lu Dotatate/Lutathera PRRT is right for you.
Here at Revive Hormone Clinic, we understand coping with a rare cancer diagnosis like NETs can be frightening and emotionally taxing. Our caring doctors are here to provide integrative, personalized support throughout your treatment, including: We will help empower each NETs patient to not just survive, but thrive in the midst of this challenging diagnosis. Schedule a consultation at our hormone clinic today.

Our Services

Get Free Consultation